BR0112461A - Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada - Google Patents

Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada

Info

Publication number
BR0112461A
BR0112461A BR0112461-7A BR0112461A BR0112461A BR 0112461 A BR0112461 A BR 0112461A BR 0112461 A BR0112461 A BR 0112461A BR 0112461 A BR0112461 A BR 0112461A
Authority
BR
Brazil
Prior art keywords
components
therapeutically active
active components
compositions containing
increased solubility
Prior art date
Application number
BR0112461-7A
Other languages
English (en)
Inventor
Orest Olejnik
D Edward
S Kerslake
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814167&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0112461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0112461A publication Critical patent/BR0112461A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçõES QUE CONTêM COMPONENTES TERAPEUTICAMENTE ATIVOS TENDO UMA SOLUBILIDADE AUMENTADA". Composições que incluem componentes terapeuticamente ativos, componentes que aumentam a solubilidade que não as ciclodextrinas, e componentes de óxi-cloro, em que os componentes de óxi-cloro são eficazes de modo substancial como conservantes. Em uma modalidade os componentes de óxi-cloro são úteis para a preservação dos componentes terapeuticamente ativos. Em uma modalidade, os componentes de óxi-cloro incluem componentes de clorito. Em uma modalidade utilizável, os componentes de aumento da solubilidade incluem a carbóxi metil celulose.
BR0112461-7A 2000-07-14 2001-07-09 Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada BR0112461A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21820600P 2000-07-14 2000-07-14
PCT/US2001/021551 WO2002005822A2 (en) 2000-07-14 2001-07-09 Compositions containing therapeutically active components having enhanced solubility

Publications (1)

Publication Number Publication Date
BR0112461A true BR0112461A (pt) 2003-07-22

Family

ID=22814167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112461-7A BR0112461A (pt) 2000-07-14 2001-07-09 Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada

Country Status (23)

Country Link
US (2) US6562873B2 (pt)
EP (2) EP1301210A2 (pt)
JP (1) JP2004503593A (pt)
KR (1) KR20030023700A (pt)
CN (1) CN1441679A (pt)
AR (1) AR035039A1 (pt)
AU (2) AU7326801A (pt)
BR (1) BR0112461A (pt)
CA (1) CA2416169C (pt)
CY (1) CY1113391T1 (pt)
DK (1) DK2153819T3 (pt)
ES (1) ES2392636T3 (pt)
HU (1) HU230383B1 (pt)
IL (2) IL153322A0 (pt)
MX (1) MXPA02012206A (pt)
NO (1) NO331816B1 (pt)
NZ (1) NZ522610A (pt)
PL (1) PL361027A1 (pt)
PT (1) PT2153819E (pt)
RU (1) RU2291685C2 (pt)
TW (1) TWI287992B (pt)
WO (1) WO2002005822A2 (pt)
ZA (1) ZA200209877B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112461A (pt) * 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
CN103143022A (zh) * 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
KR20110025760A (ko) * 2008-05-19 2011-03-11 알콘 리서치, 리미티드 카복시비닐 폴리머 및 포비돈 폴리머를 포함하는 약제학적 조성물
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US8283350B2 (en) * 2008-08-01 2012-10-09 Alpha Synergy Development, Inc. Compositions and methods for reducing capillary permeability
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
EP2555751B8 (en) 2010-04-03 2018-02-14 Praful Doshi Methods of coating a contact lens
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
AU2011237677A1 (en) * 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
WO2012041910A1 (de) 2010-10-01 2012-04-05 Elektra Management S.R.O. Lösung von guanidinium-verbindungen, verfahren unter einsatz dieser lösung sowie deren verwendung
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
KR102017922B1 (ko) 2011-12-07 2019-09-03 알러간, 인코포레이티드 염-민감성 유액 시스템을 사용한 사람 눈물막으로의 효율적인 지질 전달 방법
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JP5933033B2 (ja) 2012-01-20 2016-06-08 アラタナ セラピューティクス エン ヴェー 点眼剤組成物
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
KR20170129823A (ko) * 2015-03-19 2017-11-27 알러간, 인코포레이티드 브리모니딘 및 티몰롤의 고정된 용량 조합
KR102275012B1 (ko) 2016-08-12 2021-07-07 실크 테크놀로지스 리미티드 염증 치료용 실크 유래 단백질
AU2018265257B2 (en) * 2017-05-11 2020-08-06 Vyluma Inc. Atropine pharmaceutical compositions
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
US20230218611A1 (en) 2020-04-29 2023-07-13 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP2021183606A (ja) * 2020-05-20 2021-12-02 千寿製薬株式会社 ブリモニジンを含有する液体製剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286080A (pt) * 1961-11-30
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4145421A (en) * 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
CA2133966C (en) 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1994016685A1 (en) 1993-01-28 1994-08-04 University Of Iowa Research Foundation Ophthalmic uses of signa agonists
WO1995010280A1 (en) 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
WO1998047878A1 (en) 1997-04-18 1998-10-29 Abbott Laboratories A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione
AU2870899A (en) 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
ATE245451T1 (de) 1998-04-07 2003-08-15 Alcon Lab Inc Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE69923987T2 (de) * 1998-10-08 2006-11-02 Karagoezian, Hampar L., San Juan Capistrano Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
US6514504B1 (en) * 1999-08-18 2003-02-04 The Procter & Gamble Company Discontinuous films from skin care compositions
BR0112461A (pt) * 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
ZA200209877B (en) 2003-09-29
US20030153530A1 (en) 2003-08-14
NO20030153D0 (no) 2003-01-13
TWI287992B (en) 2007-10-11
IL153322A (en) 2011-01-31
HUP0301405A3 (en) 2006-02-28
IL153322A0 (en) 2003-07-06
RU2291685C2 (ru) 2007-01-20
PT2153819E (pt) 2012-11-14
US20020071874A1 (en) 2002-06-13
JP2004503593A (ja) 2004-02-05
PL361027A1 (en) 2004-09-20
AU7326801A (en) 2002-01-30
AU2001273268B2 (en) 2005-08-25
US6562873B2 (en) 2003-05-13
ES2392636T3 (es) 2012-12-12
WO2002005822A3 (en) 2002-05-02
NO20030153L (no) 2003-01-13
DK2153819T3 (da) 2012-12-03
MXPA02012206A (es) 2003-06-04
NZ522610A (en) 2004-11-26
AR035039A1 (es) 2004-04-14
WO2002005822A2 (en) 2002-01-24
EP1301210A2 (en) 2003-04-16
NO331816B1 (no) 2012-04-10
CA2416169A1 (en) 2002-01-24
HU230383B1 (hu) 2016-03-29
KR20030023700A (ko) 2003-03-19
HUP0301405A2 (hu) 2003-08-28
EP2153819A2 (en) 2010-02-17
CY1113391T1 (el) 2016-06-22
CA2416169C (en) 2008-09-23
EP2153819B1 (en) 2012-09-05
EP2153819A3 (en) 2010-05-12
CN1441679A (zh) 2003-09-10

Similar Documents

Publication Publication Date Title
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
AR030245A1 (es) Composiciones de gel que contienen metronidazol
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
ES2195866T3 (es) Composiciones acidas multiusos.
ATE185066T1 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
DE60105322D1 (de) Wässerige zusammensetzung enthaltend amphotericin b
DE69932510D1 (de) Vaskularisierungsinhibitoren
NO20022201L (no) Lösninger inneholdende Epinastin
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
WO2003066597A3 (en) Guanidino compounds
NO20031648D0 (no) Farmasöytiske lösninger av modafinilforbindelser
BRPI0414979A (pt) preparação sólida
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel
BR0014905A (pt) Produto de tecido antivìrus e processo para produzir o mesmo
BRPI0611526A2 (pt) composição tópica contendo gelatina
ES2160834T3 (es) Derivado de fenil pirimidina opticamente activo como agente analgesico.
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
BR9911769A (pt) Composições que contêm dextrina para prevenir as aderências cirúrgicas
RS50355B (sr) Formulacije eritropoietina sa više doza
ATE241640T1 (de) Fusidinsäure-derivate
BR0009289A (pt) Uso de inibidores da vasopeptidase para tratar angina pectoris
RS50074B (sr) Farmaceutski preparat koji sadrži paracetamol i drotaverin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.